EIT Evaluation of the Impact of Inhaled Nitric Oxide on Ventilation/Perfusion Mismatch in ARDS Patients Receiving Noninvasive Respiratory Support

Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-80
SponsorMing Zhong

About this trial

This study aimed to quantitatively evaluate the immediate effect of inhaled nitric oxide on the ventilation / perfusion ratio in ARDS patients receiving nasal high flow oxygen therapy or noninvasive ventilation using electrical impedance tomography.

Eligibility criteria

Qualifiers

Age ≥ 18 years, gender unlimited;

Non invasive ventilation (NIV) with PEEP or CPAP ≥ 5 cmH2O or nasal high flow oxygen therapy (hfnc) with flow rate ≥ 30 l/min met the diagnostic criteria of non intubated ARDS according to the new global definition of ARDS: pao2/fio2 ≤ 300MMHG or spo2/fio2 ≤ 315 (SpO2 ≤ 97%);

Patients with spontaneous breathing and clear consciousness can cooperate with instructions and hold breath for ≥ 8s;

Patients with spontaneous breathing and clear consciousness can cooperate with instructions and hold breath for ≥ 8s;

Disqualifiers

There are signs of worsening respiratory failure requiring immediate intubation: respiratory rate > 40 times / min with severe use of auxiliary respiratory muscles or contradictory breathing, or Paco ₂ > 50 mmHg and pH < 7.25;

Hemodynamic instability or the presence of refractory shock; That is, the vasoactive drugs increased by more than 30% within 6 hours, or the norepinephrine dose exceeded 0.5 μ g /kg/min;

There are contraindications to EIT monitoring, such as thoracic implantable defibrillator / pacemaker, large area of severe skin damage on the chest, serious allergy to electrode patches, etc;

There are contraindications to the use of iNO: such as severe left ventricular dysfunction, active bleeding, etc;

Trial design

Treatments tested in this trial

  • Inhale different doses of nitric oxide
  • Inhale different doses of nitric oxide

Treatment groups

40 Participants
are divided into 2 treatment groups

Sponsors and collaborators

Ming Zhong

Lead sponsor

Shanghai Zhongshan Hospital

Sponsor institution